KAMPALA - Dr Matthias Magoola says the US Patent and Trademark Office (USPTO) has granted a patent for his invention of the first treatment of cancer using a novel composition of a guided Ribonucleic ...

Researchers determined the clinical classification of more than 90% of potential BRCA2 variants of uncertain significance in ...

In a landmark achievement for both Uganda and the global medical community, the United States Patent and Trademark Office ...

Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...

Bristol Myers Squibb's FDA nod for Breyanzi (liso-cel) in relapsed/refractory CLL/SLL boosts its CAR T-cell portfolio, ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Vertex Pharmaceuticals announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.A novel ...